Roche’s he­mo­phil­ia drug slash­es bleed­ing rate, boost­ing block­buster pro­jec­tions — but doubts on safe­ty linger

Roche served up an­oth­er por­tion of late-stage da­ta on its he­mo­phil­ia drug emi­cizum­ab (ACE910), un­der­scor­ing why an­a­lysts be­lieve the Swiss phar­ma gi­ant has an­oth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER